US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CKD can progress to kidney failure requiring dialysis or kidney transplantation and is the leading cause of kidney failure in the U.S.
“CKD can progress to kidney failure requiring dialysis or kidney transplantation and is the leading cause of kidney failure in the U.S. (5).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [5]
The report’s ESRD discussion (page not provided) confirms that people with kidney failure receive dialysis or kidney transplants. It does not state that CKD is the leading cause of kidney failure in the U.S., and the passages do not explicitly describe progression from CKD to kidney failure. (LLM, conf=0.78)
Experimental — accuracy not yet measuredCKD is the leading cause of end-stage kidney disease in the U.S.
“CKD can progress to kidney failure requiring dialysis or kidney transplantation and is the leading cause of end-stage kidney disease (ESKD) in the U.S. (5).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [5]
The report’s opening section identifies CKD and end-stage renal disease (ESRD) as populations covered by its U.S. surveillance data, and the ESRD discussion reports dialysis and transplant counts. Neither passage says CKD is the leading cause of ESRD or ranks its causes; searches for that claim and for CKD progression to kidney failure found no supporting passage in our copy. (LLM, conf=0.74)
Experimental — accuracy not yet measuredSGLT2i and GLP-1RA are recommended in patients with CKD with type 2 diabetes by the American Diabetes Association and KDIGO clinical guidelines.
“Sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) are recommended in patients with CKD with type 2 diabetes by the American Diabetes Association and KDIGO (Kidney Disease: Improving Global Outcomes) clinical guidelines.15,16”
From Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States (2023) · cites this paper as [16]
The annual report passage describing its scope (section titled “US Renal Data System 2020 Annual Data Report,” page unavailable) concerns CKD surveillance, not treatment recommendations. Searches for SGLT2 inhibitors, GLP-1 receptor agonists, and ADA or KDIGO guidelines found no passage in our copy addressing the claimed recommendations. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473 · see citing works
11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344 · see citing works
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 262 · see citing works
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108 · see citing works
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2022.100564 · Cited by 33 · see citing works
“Clinical Modification diagnosis codes provided by the US Renal Data System.(19) We excluded diagnoses related to type 1 diabetes (International Classification of Diseases, Ninth Revision, Clinical Modification: 250.”
Self-citationAbegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01160-8 · Cited by 15 · see citing works
Patient perceived quality of nursing care in hemodialysis: a meta-synthesis
Balouchi, A., Ebadi, A., Parvizy, S., & Sharif Nia, H. (2021) · Healthcare in Low-resource Settings · doi:10.4081/hls.2021.9320 · Cited by 4 · see citing works
- Authors
- Johansen, K. L., Chertow, G. M., Foley, R. N., Gilbertson, D. T., Herzog, C. A., Ishani, A., Israni, A. K., Ku, E., Kurella Tamura, M., Li, S., Li, S., Liu, J., Obrador, G. T., O’Hare, A. M., Peng, Y., Powe, N. R., Roetker, N. S., St. Peter, W. L., Abbott, K. C., Chan, K. E., Schulman, I. H., Snyder, J., Solid, C., Weinhandl, E. D., Winkelmayer, W. C., & Wetmore, J. B.
- ORCID
- Johansen, Kirsten L.
- Chertow, Glenn M.
- Gilbertson, David T.
- Herzog, Charles A.
- Ishani, Areef
- Israni, Ajay K.
- Ku, Elaine
- Li, Shuling
- Li, Suying
- Liu, Jiannong
- Obrador, Gregorio T.
- O’Hare, Ann M.
- Powe, Neil R.
- Roetker, Nicholas S.
- Abbott, Kevin C.
- Schulman, Ivonne H.
- Snyder, Jon
- Solid, Craig
- Weinhandl, Eric D.
- Wetmore, James B.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 77
- Issue
- 4
- Pages
- A7-A8
- ISSN
- 0272-6386 (ISSN-L)
- PMC
- PMC8148988
- OpenAlex
- W3139470068
- Cited by
- 724
- References
- 0
- Citations by year
- 2026: 59 · 2025: 122 · 2024: 174 · 2023: 143 · 2022: 158 · 2021: 62 · 2020: 4
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u01dk102150-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK102150)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (75N94019C00006)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- chronic kidney disease, end-stage renal disease, kidney disease epidemiology, dialysis, kidney transplantation, United States
- MeSH terms
- Data Systems, Annual Reports as Topic, Humans, Kidney Failure, Chronic, United States, Centers for Medicare and Medicaid Services, U.S., National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
